- Compare the incidence of biochemical failure (prostate-specific antigen (PSA) greater
than 2 ng/mL at 6 or more months after initiation of radiotherapy and PSA rising from
nadir level by at least 50%), development of metastases, and survival in patients
treated with these regimens.

- Compare the acute and late radiation-induced side effects of these regimens in this
patient population.

- Compare aspects of quality of life, health economics, models of normal tissue, and
tumor control in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
prostate-specific antigen, T stage, and Gleason score. Patients are randomized to one of two
treatment arms.

Start Date:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.